Acalabrutinib alone or in combination with rituximab for follicular lymphoma: An open-label study

被引：2

作者：

Strati, Paolo ^{[1
]}

Champion, Rebecca ^{[2
]}

Coleman, Morton ^{[3
]}

Smith, Sonali M. ^{[4
]}

Venugopal, Parameswaran ^{[5
]}

Martin, Peter ^{[6
]}

Wood, Andrew ^{[7
]}

Miller, Kara ^{[8
]}

Christian, Beth ^{[9
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[2] Norton Canc Inst, Louisville, KY USA

[3] Weill Cornell Med, Clin Res Alliance, New York, NY USA

[4] Univ Chicago, Med Ctr, Chicago, IL USA

[5] Rush Univ, Med Ctr, Chicago, IL USA

[6] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA

[7] AstraZeneca, Cambridge, England

[8] AstraZeneca, South San Francisco, CA USA

[9] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2024年 / 205卷 / 06期

关键词：

B-cell lymphoma; Bruton tyrosine kinase; non-Hodgkin lymphoma; TYROSINE KINASE INHIBITOR; B-CELLS; IBRUTINIB; ACP-196;

D O I：

10.1111/bjh.19787

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Acalabrutinib is a selective, second-generation Bruton tyrosine kinase inhibitor. In this open-label, parallel-group study, patients with relapsed/refractory (R/R) follicular lymphoma (FL) were randomised to either acalabrutinib monotherapy or acalabrutinib plus rituximab. An additional cohort of patients with treatment-naive (TN) FL received only the acalabrutinib-rituximab combination. Acalabrutinib-rituximab was well tolerated and active in R/R and TN FL; in the TN cohort the overall response rate was 92.3% with most remissions lasting over 4 years. Acalabrutinib monotherapy was also well tolerated and active in R/R FL. These results support further study of acalabrutinib alone and in combination with rituximab in FL.

引用

页码：2248 / 2253

页数：6

共 50 条

[31] Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial
Ravani, Pietro
Rossi, Roberta
Bonanni, Alice
Quinn, Robert R.
Sica, Felice
Bodria, Monica
Pasini, Andrea
Montini, Giovanni
Edefonti, Alberto
Belingheri, Mirco
De Giovanni, Donatella
Barbano, Giancarlo
Degl'Innocenti, Ludovica
Scolari, Francesco
Murer, Luisa
Reiser, Jochen
Fornoni, Alessia
Ghiggeri, Gian Marco
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2015, 26 (09): : 2259 - 2266
[32] Interim analysis: Open-label extension study of leniolisib for patients with APDS
Rao, V. Koneti
Kulm, Elaine
Sediva, Anna
Plebani, Alessandro
Schuetz, Catharina
Shcherbina, Anna
Dalm, Virgil A.
Trizzino, Antonino
Zharankova, Yulia
Webster, Sharon
Orpia, Alanvin
Koeurorholz, Julia
Lougaris, Vassilios
Rodina, Yulia
Radford, Kath
Bradt, Jason
Relan, Anurag
Holland, Steven M.
Lenardo, Michael J.
Uzel, Gulbu
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (01) : 265 - 274.e9
[33] Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase study
Dreyling, Martin
Jurczak, Wojciech
Jerkeman, Mats
Silva, Rodrigo Santucci
Rusconi, Chiara
Trneny, Marek
Offner, Fritz
Caballero, Dolores
Joao, Cristina
Witzens-Harig, Mathias
Hess, Georg
Bence-Bruckler, Isabelle
Cho, Seok-Goo
Bothos, John
Goldberg, Jenna D.
Enny, Christopher
Traina, Shana
Balasubramanian, Sriram
Bandyopadhyay, Nibedita
Sun, Steven
Vermeulen, Jessica
Rizo, Aleksandra
Rule, Simon
LANCET, 2016, 387 (10020) : 770 - 778
[34] Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study
Gibiansky, Ekaterina
Gibiansky, Leonid
Buchheit, Vincent
Frey, Nicolas
Brewster, Michael
Fingerle-Rowson, Gunter
Jamois, Candice
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (09) : 1935 - 1945
[35] Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas
Puvvada, Soham D.
Guillen-Rodriguez, Jose
Kumar, Abhijeet
Inclan, Lora
Heard, Kara
Rivera, Xavier I.
Anwer, Faiz
Schatz, Jonathan H.
Mahadevan, Daruka
Persky, Daniel O.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (01) : 58 - 64
[36] A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease
Daoussis, Dimitrios
Melissaropoulos, Konstantinos
Sakellaropoulos, Georgios
Antonopoulos, Ioannis
Markatseli, Theodora E.
Simopoulou, Theodora
Georgiou, Panagiotis
Andonopoulos, Andrew P.
Drosos, Alexandros A.
Sakkas, Lazaros
Liossis, Stamatis-Nick
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2017, 46 (05) : 625 - 631
[37] Safety and Efficacy of Combination Therapy with Fludarabine, Mitoxantrone, and Rituximab Followed by Yttrium-90 Ibritumomab Tiuxetan and Maintenance Rituximab as Front-Line Therapy for Patients With Follicular or Marginal Zone Lymphoma
Karmali, Reem
Kassar, Mohamad
Venugopal, Parameswaran
Shammo, Jamile M.
Fung, Henry C.
Bayer, Robert
O'Brien, Teresa
Gregory, Stephanie A.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (06) : 467 - 474
[38] Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry Study
Junlen, H. R.
Peterson, S.
Kimby, E.
Lockmer, S.
Linden, O.
Nilsson-Ehle, H.
Erlanson, M.
Hagberg, H.
Radlund, A.
Hagberg, O.
Wahlin, B. E.
LEUKEMIA, 2015, 29 (03) : 668 - 676
[39] Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study
Fowler, Nathan
Kahl, Brad S.
Lee, Peter
Matous, Jeffrey V.
Cashen, Amanda F.
Jacobs, Samuel A.
Letzer, Jeffrey
Amin, Bipinkumar
Williams, Michael E.
Smith, Sonali
Saleh, Alfred
Rosen, Peter
Shi, Hongliang
Parasuraman, Sudha
Cheson, Bruce D.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (25) : 3389 - 3395
[40] Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme
Muhic, Aida
Poulsen, Hans Skovgaard
Sorensen, Morten
Grunnet, Kirsten
Lassen, Ulrik
JOURNAL OF NEURO-ONCOLOGY, 2013, 111 (02) : 205 - 212

← 1 2 3 4 5 →